Emerging treatments for primary sclerosing cholangitis

Eduardo A. Rodriguez, Elizabeth J. Carey, Keith D. Lindor

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Introduction: Primary sclerosing cholangitis (PSC) is a chronic, cholestatic, idiopathic liver disease that can progress to end-stage liver disease, cirrhosis and cholangiocarcinoma. PSC is an uncommon and highly heterogeneous disease, associated with inflammatory bowel disease and a complex pathophysiology. To date, no medical therapies have proved effective. The only available treatment for end-stage PSC is liver transplant, but recurrence is a significant complication. Areas covered: This review will explore previously tested treatments, discuss current treatment strategies and present viewpoints about future emerging therapies in PSC. We searched PubMed using the noted keywords. We included data from full-text articles published in English. Further relevant articles were identified from the reference lists of review articles. Expert commentary: The development of new therapies in PSC has been challenging. However, with greater awareness of the disease nowadays, new insights into the disease may help in the design of future therapeutic agents in PSC and ultimately in effective therapies.

Original languageEnglish (US)
Pages (from-to)451-459
Number of pages9
JournalExpert Review of Gastroenterology and Hepatology
Issue number5
StatePublished - May 4 2017


  • antibiotics
  • antifibrotic agents
  • fecal microbiota transplantation
  • obeticholic acid
  • Primary sclerosing cholangitis
  • ursodeoxycholic acid

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Emerging treatments for primary sclerosing cholangitis'. Together they form a unique fingerprint.

Cite this